GlassScriptPhysician profile
Ronald D Chattin
NPI 1770597171
$2,833.65
in general payments reported to CMS, 2019-2025
28 companies · $15.67 in 2025
The $15.67 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79.56 · 2020: $43.44 · 2021: $1,322 · 2022: $1,030 · 2023: $343 · 2025: $15.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $358.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $426.80 | 2020-2023 | Ozempic, Rybelsus |
| Pfizer INC. | $351.14 | 2021-2023 | |
| Abbvie INC. | $283.89 | 2021-2025 | Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $214.45 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $185.73 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $175.87 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $166.88 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $149.68 | 2021-2023 | Xifaxan |
| Glaxosmithkline, LLC. | $133.53 | 2021-2023 | Trelegy Ellipta |
| Abbott Laboratories | $113.11 | 2021-2022 | |
| Lilly USA, LLC | $102.32 | 2019-2023 | Mounjaro, Trulicity |
| Amarin Pharma, INC. | $87.12 | 2019-2022 | |
| Dexcom, INC. | $56.70 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $48.90 | 2022-2023 | Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $44.96 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $41.93 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $38.28 | 2021 | |
| Daiichi Sankyo INC. | $34.28 | 2021 | |
| Medtronic, INC. | $28.49 | 2022 | |
| Redhill Biopharma INC. | $26.42 | 2021 | |
| Sunovion Pharmaceuticals INC. | $18.92 | 2019 | |
| Xeris Pharmaceuticals, INC. | $17.76 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.10 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $15.64 | 2022 | |
| Exact Sciences Corporation | $14.91 | 2023 | Cologuard Collection Kit |
| Jazz Pharmaceuticals INC. | $14.09 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.83 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Chattin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.